NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ImmuneBiotech

ImmuneBiotech

Private
LundHealthcare & Life Scienceshttps://immunebiotech.com/

Last Round

Debt

Jul 8, 2026

Total Funding Raised

$165.79M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

ImmuneBiotech is a biotechnology company that develops, markets, and commercializes therapeutically effective probiotic products designed with pharmaceutical precision to manage gastrointestinal and neurological conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, D2C Brands, Drug Discovery, E-commerce

Business Model

B2C

Customer Profile

Hardware Sales, Data as a Service

AI Layer

Non-AI

Keywords

probiotic supplementmulti-strain probioticsgut microbiomegut healthdigestive healthIBSleaky gutdysbiosisimmune modulationintestinal permeabilitymicrobiome therapeuticsclinically validated probioticsD2CB2B2Ccompanion probiotics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmuneBiotech Comps

Public and private peers based on sector, stage, and business model.

ImmuneBiotech comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ImmuneBiotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJul 8, 2026
Growth EquityMay 4, 2026
VC RoundJan 20, 2021
Series AJan 24, 2019

Key People

Founding team and executive leadership

Shahram Lavasani

Founder & CEO

Founding Team

ImmuneBiotech Investors

Notable investors and investment history

ImmuneBiotech investors
InvestorRounds
Janus Henderson GroupGrowth Equity
RA Capital ManagementGrowth Equity
Omega FundsGrowth Equity
Blue Owl CapitalGrowth Equity
OrbiMedGrowth Equity
Almi Invest ABDebt
Novo HoldingsGrowth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2026

    $165M round led by OrbiMed.

  • Jan 2, 2026

    Monthly visitors grew 206% MoM, from 53 to 162.

ImmuneBiotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmuneBiotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmuneBiotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersLund
Employee Range5
Year FoundedN/A
Last FundingJul 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.